May 7, 2010, Lansen Pharmaceutical Holdings Limited launched its initial public offering (IPO) of 141,350,000 shares at HKD 3.91 each for a Hong Kong Stock Exchange main board listing, under the stock code of 000503.HK. The raised funds reached a total of HKD 552,678,500.

Lansen Pharmaceutical Holding Limited engages in the development, production and sale of specialty prescription western pharmaceuticals for the treatment of rheumatic diseases in China. By the end of 2009, the company’s sale and distribution network covers more than 1,000 hospitals across the country.

Jingtian & Gongcheng represented the underwriter in the listing.